Quotient Bioresearch Revenue and Competitors
Estimated Revenue & Valuation
- Quotient Bioresearch's estimated annual revenue is currently $50.3M per year.
- Quotient Bioresearch's estimated revenue per employee is $201,000
Employee Data
- Quotient Bioresearch has 250 Employees.
Quotient Bioresearch's People
Name | Title | Email/Phone |
---|
Quotient Bioresearch Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $13.9M | 69 | -13% | N/A | N/A |
#2 | $110.3M | 549 | -3% | N/A | N/A |
#3 | $14.1M | 70 | 1% | N/A | N/A |
#4 | $1051.4M | 5231 | -5% | N/A | N/A |
#5 | $55.9M | 278 | 22% | N/A | N/A |
#6 | $50.3M | 250 | N/A | N/A | N/A |
#7 | $2.2M | 22 | 214% | N/A | N/A |
#8 | $1.4M | 7 | -87% | N/A | N/A |
#9 | $68.1M | 339 | 17% | N/A | N/A |
#10 | $19.5M | 97 | 0% | N/A | N/A |
What Is Quotient Bioresearch?
Join the new Radiolabelled Sciences LinkedIn page: \nhttps://www.linkedin.com/company/pharmaron-radiolabelled-sciences-division\n\nPharmaron is a premier R&D service provider supporting the life science industry. Founded in 2003, Pharmaron has invested in its people and facilities having established diverse drug R&D service capabilities, ranging from synthetic, medicinal and analytical chemistry, biology, DMPK, pharmacology, drug safety assessment, radiochemistry and isotopically labelled metabolism, chemical & pharmaceutical development to clinical development, including applications of 14C microtracer AMS technology. With operations in China, US and UK staffed by over 4,500 employees, Pharmaron has an excellent track record in the delivery of R&D solutions to its partners in North America, Europe, Japan and China. \nFor more information, visit: www.pharmaron.com
keywords:N/AN/A
Total Funding
250
Number of Employees
$50.3M
Revenue (est)
N/A
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $75.1M | 253 | 3% | N/A |
#2 | $81M | 254 | 2% | N/A |
#3 | $92.7M | 257 | 6% | N/A |
#4 | $82.9M | 260 | 1% | N/A |
#5 | $47.4M | 261 | 2% | N/A |